Compare Global X Copper Miners ETF (COPX) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global X Copper Miners ETF vs TG Therapeutics Inc — how do they compare? Global X Copper Miners ETF trades at $85.75 (market cap $7.10B), while TG Therapeutics Inc trades at $55 (market cap $8.16B). The key difference: Global X Copper Miners ETF and TG Therapeutics Inc are close in size by market cap, and TG Therapeutics Inc is trading nearer its 52-week high, Global X Copper Miners ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Global X Copper Miners ETF for 51 Days and TG Therapeutics Inc for 16 Days on average.
| COPX | TGTX | |
|---|---|---|
Market Cap | $7.10B | $8.16B |
Volume | 2,871,128 | 1,735,121 |
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $96.45 | $59.06 |
52-Week Low | $57.43 | $26.94 |
Typical Hold Time | 51 Days | 16 Days |
Enterprise Value | — | $8.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
COPX (Global X Copper Miners ETF) trades at $85.75, up 2.6% with a bearish technical outlook from moving averages. The ETF faces mixed sentiment as copper demand surges due to AI and electrification trends, while miner stocks lag behind metal prices. Recent articles highlight copper's strategic importance but note global surplus concerns and Federal Reserve policy impacts on mining equities.
Outlook hinges on copper price sustainability amid AI-driven demand, though miner valuations remain pressured. Key risks include global copper surplus projections and Fed policy volatility. Opportunities exist from structural copper deficits and operational leverage if metal prices hold near record highs above $6.85/lb (GuruFocus, September 8, 2026).
TG Therapeutics (TGTX) trades at $55.37, up 4.57% today, but faces a bearish technical signal with recent earnings misses. Strong revenue growth is driven by BRIUMVI, with 2026 guidance raised to $950 million, though profitability is pressured by investments. A shareholder investigation and volatile cash flows add uncertainty, while analyst consensus remains bullish with an $80.50 price target.
The outlook hinges on BRIUMVI's market share gains and subcutaneous formulation progress, offering upside if execution succeeds. Risks include the fiduciary investigation, competitive pressures, and reliance on a single product. The stock presents a high-risk, high-reward opportunity, with current valuation reflecting growth expectations but vulnerable to setbacks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Global X Copper Miners ETF
COPX tracks the Solactive Global Copper Miners Total Return Index, providing broad exposure to companies worldwide involved in copper mining, refining, and exploration. It serves as an equity-based alternative to copper futures, offering a leveraged play on copper demand driven by global infrastructure and the clean energy transition.
Read more on COPX →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
